Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature
| Autor: | Xin Li, Qiumei Dong, Shijiang Xing |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Down syndrome medicine.medical_specialty Pathology Mutant Case Report Internal medicine medicine Epidermal growth factor receptor Lung cancer EGFR-TKIs resistance Lung biology business.industry Incidence (epidemiology) respiratory system medicine.disease respiratory tract diseases trisomy 21 medicine.anatomical_structure non-small-cell lung cancer Egfr mutation biology.protein EGFR mutation Trisomy business |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Xin Li 1 , Shijiang Xing 1 and Qiumei Dong 2 1 Department of Medical Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, China 2 Department of Medical Oncology, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China Correspondence to: Qiumei Dong, email: hrbsh@163.com Keywords: Down syndrome, non-small-cell lung cancer, EGFR mutation, trisomy 21, EGFR-TKIs resistance Received: February 07, 2017 Accepted: April 03, 2017 Published: April 25, 2017 ABSTRACT Background : Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers. Methods: The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed. Results: In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer. Conclusions: Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|